STOCK TITAN

Moderna - MRNA STOCK NEWS

Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

About Moderna

Moderna, Inc. is a commercial-stage biotechnology company renowned for pioneering messenger RNA (mRNA) therapeutics, a revolutionary in vivo drug modality that enables the body’s cells to produce human proteins and antibodies. This groundbreaking approach has transformed how medicines are developed, offering novel treatment avenues for infectious diseases, oncology, rare genetic disorders, and other serious conditions. By harnessing its proprietary mRNA platform, Moderna has established a comprehensive portfolio of potential therapeutics and vaccines, positioned at the nexus of science, technology, and healthcare innovation.

Innovative mRNA Technology Platform

The company’s core technology leverages synthetic mRNA to instruct patient cells to express therapeutic proteins. This innovative platform addresses traditionally undruggable targets and provides a versatile alternative to conventional therapies. With an extensive intellectual property estate that encompasses numerous patent applications and claims across novel nucleotide chemistries and drug compositions, Moderna’s expertise underpins its robust research and development pipeline. Its approach emphasizes rapid development, scalability, and the flexibility to target a wide array of disease conditions.

Clinical Pipeline and Therapeutic Areas

Moderna’s diversified clinical pipeline spans multiple therapeutic categories, including:

  • Infectious Diseases: The company gained widespread recognition for its development of an effective COVID-19 vaccine, which validated its mRNA technology on a global stage. It continues to evolve its respiratory vaccine portfolio with candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and other emerging infectious pathogens.
  • Oncology: Moderna is exploring mRNA-based immunotherapies designed to harness the immune system’s potential to target cancer cells, including individualized neoantigen therapies. These therapeutic approaches aim to offer precision treatment modalities in oncology.
  • Rare Diseases: The company’s strategy includes developing mRNA-based treatments for rare genetic disorders, where traditional drug modalities often fall short. By targeting metabolic disorders and other conditions with limited treatment options, Moderna is working toward addressing significant unmet medical needs.
  • Latent and Other Diseases: Beyond infectious and oncological applications, Moderna’s pipeline incorporates next-generation vaccines and therapeutics targeting latent viruses and other challenging medical conditions.

Market Position and Value Proposition

Positioned as a trailblazer in mRNA therapeutics, Moderna combines a deep understanding of biological mechanisms with advanced pharmaceutical science. Its core value proposition lies in the ability to quickly design and develop mRNA-based candidates, reducing both development timelines and manufacturing complexity relative to traditional modalities. This agility has not only provided a rapid response to emergent global health challenges but has also established the company as a significant player in the biotechnology sector.

Business Model and Operational Excellence

Moderna generates revenue through its commercialized vaccine products and ongoing clinical collaborations across various therapeutic areas. The company’s operational model is characterized by strategic partnerships, efficient research and development processes, and rigorous adherence to regulatory standards. Its focus on cost efficiencies and portfolio prioritization further enhances its competitive edge. This balanced approach underscores Moderna’s commitment to delivering innovative, scalable, and safe mRNA medicines.

Commitment to Scientific Rigor and Transparency

Underpinned by a culture of scientific excellence and continuous innovation, Moderna maintains a high standard of transparency and rigor in its research. The company’s clinical development programs are structured to provide clear evidence of safety and efficacy, supporting its authority in the biotech field. This commitment enables healthcare providers and analysts to gain a deep understanding of the interconnected dynamics within its research and development initiatives.

Summary

In summary, Moderna stands at the forefront of the mRNA revolution, with a proven platform that redefines traditional therapeutic approaches. Its comprehensive pipeline, covering infectious diseases, oncology, rare disorders, and beyond, is a testament to the transformative potential of mRNA technology. As a company deeply embedded within the biopharmaceutical landscape, Moderna continues to drive innovation, operational excellence, and advancements in patient care, reinforcing its role as a key contributor to the future of medicine.

Rhea-AI Summary

Moderna reported 2024 product sales of $3.0-3.1 billion (including $1.7B in US) and ended with approximately $9.5B cash balance. The company projects 2025 revenue of $1.5-2.5B, mainly from Spikevax and mRESVIA sales, with an expected year-end cash balance of $6.0B.

The company plans significant cost reductions: $1.0B in 2025 and additional $0.5B in 2026. Key pipeline updates include FDA review of next-generation COVID-19 vaccine (mRNA-1283) with PDUFA date of May 31, 2025, positive Phase 3 data for flu/COVID combination vaccine, and ongoing trials for CMV and norovirus vaccines. The Phase 3 melanoma trial with individualized neoantigen therapy completed enrollment in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.8%
Tags
none
-
Rhea-AI Summary

Carisma Therapeutics (NASDAQ: CARM) announced a strategic restructuring, including discontinuation of CT-0525 development and a 34% workforce reduction. The company will redirect focus to its in vivo macrophage engineering platform for fibrosis, oncology, and autoimmune disease therapies.

Key developments include: plans to nominate a liver fibrosis development candidate in Q1 2025; ongoing collaboration with Moderna on multiple oncology and autoimmune programs; and expected restructuring costs of approximately $2.7 million. Three senior executives, including the CFO, General Counsel, and SVP of Human Resources, will depart by December 31, 2024.

The decision to discontinue the anti-HER2 program was based on competitive landscape assessment and recent developments in anti-HER2 therapies affecting antigen loss/downregulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
-
Rhea-AI Summary

Moderna (MRNA) has announced its upcoming participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 4th at 1:20pm ET, followed by the Piper Sandler 36th Annual Healthcare Conference on December 5th at 10:30am ET.

Live webcasts of both presentations will be accessible through the Investors section of Moderna's website under 'Events and Presentations.' Recordings will remain available for at least 30 days after each presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
conferences
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has been ranked as the top large employer in BioSpace's 2025 Best Places to Work report for the fourth consecutive year. The recognition highlights the company's reputation and commitment to innovation. Moderna continues to invest in employee development through initiatives like its AI Academy and AI-powered tools. The company was also recently recognized in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna's focus remains on creating an environment fostering meaningful careers while pursuing its mission of delivering multiple products in the coming years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
-
Rhea-AI Summary

Carisma Therapeutics (NASDAQ: CARM) announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed with Moderna. The therapy demonstrated ability to create CAR-M directly in vivo, reprogramming myeloid cells to target GPC3-expressing cancer cells. Pre-clinical results showed specificity for GPC3 tumor antigen with dose-dependent cytotoxicity against GPC3+ tumor cells. In both syngeneic and humanized tumor models, the therapy significantly reduced tumor burden and suppressed liver metastasis. The treatment was well-tolerated in mouse models, showing promise as an off-the-shelf treatment for GPC3+ solid tumors, including HCC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has received Health Canada approval for mRESVIA, an RSV vaccine for adults aged 60 and older. This marks Moderna's second approved product in Canada and the first mRNA vaccine against RSV. The vaccine, available in a unique pre-filled syringe format, is approved for preventing lower respiratory tract disease caused by RSV. The approval is based on Phase 3 ConquerRSV trial data involving 37,000 adults. Supply is expected in Canada in early 2025. The National Advisory Committee on Immunization recommends the vaccine for people aged 75+ and those 60+ in nursing homes, while community-dwelling adults 60+ can decide individually with their healthcare provider.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
none
Rhea-AI Summary

Moderna reported Q3 2024 financial results with revenues of $1.9 billion and GAAP net income of $13 million ($0.03 EPS). Product sales reached $1.8 billion, including $1.2 billion in U.S. sales and $0.6 billion internationally. The company reiterates 2024 expected product sales of $3.0-3.5 billion. Cost of sales decreased 77% to $514 million. R&D expenses decreased 2% to $1.1 billion, while SG&A expenses dropped 36% to $281 million. Cash position stands at $9.2 billion. The company initiated Phase 3 trials for norovirus and influenza vaccines, and expanded its Executive Committee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
-
Rhea-AI Summary

Carisma Therapeutics (Nasdaq: CARM) announced new pre-clinical data presentation on their anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC) at SITC 2024. The therapy, developed with Moderna, uses lipid nanoparticles to deliver mRNA that reprograms endogenous myeloid cells, creating an off-the-shelf treatment approach for GPC3+ solid tumors.

The data, demonstrating robust anti-tumor activity, will be presented on November 8, 2024, at the SITC Annual Meeting in Houston, Texas. The presentation focuses on targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. Two posters will be presented, including one on the pre-clinical efficacy of anti-GPC3 CAR-M and another on a Phase 1 study of anti-HER2 CAR therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
-
Rhea-AI Summary

Moderna (NASDAQ:MRNA) has announced its participation in three major healthcare conferences in November 2024. The company will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 12th at 10:00am ET, the UBS Global Healthcare Conference on November 13th at 3:30pm PT, and the Jefferies London Healthcare Conference on November 21st at 2:00pm GT. Live webcasts of all presentations will be accessible through the Investors section of Moderna's website, with replays available for at least 30 days after each event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
Rhea-AI Summary

Merck (MRK) and Moderna have initiated INTerpath-009, a Phase 3 clinical trial evaluating V940 (mRNA-4157) combined with KEYTRUDA for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer (NSCLC). The trial targets patients who didn't achieve complete response after neoadjuvant KEYTRUDA plus platinum-based chemotherapy. This marks the third Phase 3 trial for V940, focusing on earlier cancer stages. Patient enrollment has begun in Canada, expanding the companies' collaborative INTerpath clinical program which includes trials for melanoma, lung cancer, cutaneous squamous cell carcinoma, renal cell carcinoma, and urothelial carcinoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags

FAQ

What is the current stock price of Moderna (MRNA)?

The current stock price of Moderna (MRNA) is $27.72 as of April 2, 2025.

What is the market cap of Moderna (MRNA)?

The market cap of Moderna (MRNA) is approximately 10.6B.

What is Moderna's core technology?

Moderna uses a pioneering mRNA platform that instructs patient cells to produce therapeutic proteins, offering a new in vivo drug modality.

Which therapeutic areas does Moderna focus on?

Moderna’s portfolio spans infectious diseases, oncology, rare genetic disorders, and other conditions where traditional therapies may not be effective.

How does Moderna generate revenue?

Revenue is primarily generated through the commercialization of its vaccine products and strategic collaborations in the development of mRNA-based therapies.

What makes Moderna's mRNA platform unique?

The platform allows for rapid design and development of tailored therapeutics, addressing previously undruggable targets with innovative manufacturing processes.

How does Moderna maintain its competitive position?

Moderna leverages a robust intellectual property portfolio, strategic partnerships, operational efficiencies, and a strong clinical pipeline to maintain a competitive edge.

What is the significance of Moderna's COVID-19 vaccine?

The successful development and deployment of its COVID-19 vaccine validated the effectiveness of its mRNA technology, demonstrating its capability in quickly addressing global health challenges.

How does Moderna ensure safety and efficacy in its products?

Moderna adheres to rigorous clinical development protocols and regulatory standards, providing transparent and robust data from its extensive research and trials.

What are the future areas of focus for Moderna?

Moderna continues to enhance its pipeline in areas such as respiratory vaccines, cancer immunotherapies, and treatments for rare diseases, reinforcing its position in innovative medicine.
Moderna

Nasdaq:MRNA

MRNA Rankings

MRNA Stock Data

10.59B
358.52M
7.27%
72.77%
11.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE